Nexus Pharmaceuticals Revenue and Competitors

Claim your profile

Chicago, IL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Nexus Pharmaceuticals's estimated annual revenue is currently $257.3M per year.(i)
  • Nexus Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Nexus Pharmaceuticals has 1280 Employees.(i)
  • Nexus Pharmaceuticals grew their employee count by 588% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.8M3448%N/AN/A
#2
$69.3M345-4%N/AN/A
#3
$17.7M88-14%$35MN/A
#4
$13.1M6510%N/AN/A
#5
$3M36-8%N/AN/A
#6
$3.9M477%N/AN/A
#7
$35.3M31720%$289.7MN/A
#8
$3.9M4718%N/AN/A
#9
$12.9M64-4%N/AN/A
#10
$154M76619%N/AN/A

Nexus Pharmaceuticals, Inc. is a niche Generic pharmaceutical company located in 175 E Hawthorn Pkwy, Vernon Hills, Illinois, United States.

keywords:N/A

N/A

Total Funding

1280

Number of Employees

$257.3M

Revenue (est)

588%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nexus Pharmaceuticals News

2022-04-17 - Trisenox (arsenic trioxide) Market Size 2022 Segments ...

Trisenox (arsenic trioxide) Market Size 2022 Segments, Competitors Strategy, Regional Analysis, Key Players |Teva, Fresenius Kabi, Nexus Pharmaceuticals,.

2022-04-17 - Isoprenaline Market Size, Outlook And Forecast | Novartis ...

... Marathon Pharmaceuticals, Bausch Health Companies, Pfizer, Sanofi, Sterling-Winthrop, Cipla USA, Amneal Biosciences, Nexus Pharmaceuticals .

2022-04-13 - Nexus Pharmaceuticals Announces Launch of Erythromycin ...

Nexus Pharmaceuticals, a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-...

2019-09-08 - Wetlands rezoned to make way for pharmaceutical facility

During a special meeting, the board voted 5-0 to rezone two wetland areas to the west and south of the property for the Nexus Pharmaceuticals ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$536.2M15261%N/A
#2
$570.8M1664N/AN/A
#3
$300M2562N/AN/A
#4
$20240M11087-6%$58.7M